Indivior

Indivior push to diversify boosted by schizophrenia drug approval

For years, Indivior has made the bulk of its revenues from opioid addiction treatment Suboxone. ... The two approvals come as Indivior is fighting a rearguard action to protect Suboxone from a generic developed by Dr Reddy’s Laboratories.

The year of the blockbuster

Emanating from the pipelines of global pharma giants like Novartis, Johnson &Johnson and Pfizer, as well companies such as Denmark’s Novo Nordisk and Indivior and GW Pharmaceuticals, both of the ... Sublocade (buprenorphine) from Indivior:Sublocade,

Deal Watch January 2018

Licence. 350. Addex Therapeutics/ Indivior. ADX71441, selective positive allosteric modulator (PAM) for addiction (pc).

FDA panel backs Indivior’s drug to fight opioid addiction

Indivior is on course to bring a new drug to market to tackle painkiller addiction in the US, offsetting the risks to its business from generic competition. ... An FDA advisory committee backed approval of Indivior’s RBP-6000 drug by a vote of eighteen

Indivior slumps as patent dispute rises US generic spectre

company launches ahead of the appeal outcome it would be at-risk of damages if Indivior's appeal is successful. ... RBP-6000 is due for an FDA verdict by November 30 and according to Indivior could have $1bn or more sales potential.

[ Previous 5 results ] 1 2 3 [ Next 5 results ]